|
1
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
4.64
|
|
2
|
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
|
N Engl J Med
|
2013
|
3.97
|
|
3
|
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
|
Cancer Discov
|
2013
|
2.88
|
|
4
|
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
|
J Clin Oncol
|
2004
|
2.37
|
|
5
|
Defining the critical hurdles in cancer immunotherapy.
|
J Transl Med
|
2011
|
2.32
|
|
6
|
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
|
Am J Respir Crit Care Med
|
2010
|
1.94
|
|
7
|
Safety profile of RNAi nanomedicines.
|
Adv Drug Deliv Rev
|
2012
|
1.15
|
|
8
|
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
|
Melanoma Res
|
2008
|
0.89
|
|
9
|
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
|
Clin Cancer Res
|
2002
|
0.89
|
|
10
|
IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma.
|
J Immunol
|
2002
|
0.88
|
|
11
|
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.
|
J Immunother
|
2002
|
0.85
|
|
12
|
Melanoma.
|
J Natl Compr Canc Netw
|
2006
|
0.83
|